Clever Leaves Holdings Inc. (NASDAQ:CLVR) announced an expansion of its relationship with Australian medical cannabis company Cannatrek Ltd. by signing a two-year, take-or-pay basis supply agreement. The deal includes high-THC flower from Portugal, while expanding on its existing partnership for various 10% and 20% CBD oral solutions from Colombia announced in 2020.
Licensed to distribute and sell to Australian medical cannabis patients, Cannatrek has been offering 10% and 20% CBD oral solutions supplied by Clever Leaves since 2020. Broadening the reach of both companies in Australia’s thriving market, Clever Leaves will now provide a strain of high-THC flower, to be sold and distributed through Australia’s medical cannabis prescription pathway, enhancing its proposition as a B2B supplier capable of providing both pharmaceutical extracted and dry flower products.
